Notable Reporting: Can Dimension Therapeutics Inc’s Tomorrow be Different? The Stock Just Broke Its All-Time Low

Notable Reporting: Can Dimension Therapeutics Inc's Tomorrow be Different? The Stock Just Broke Its All Time Low

The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) reached all time low today, Nov, 3 and still has $3.96 target or 11.00% below today’s $4.45 share price. This indicates more downside for the $111.38M company. This technical setup was reported by If the $3.96 PT is reached, the company will be worth $12.25M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 25,516 shares traded hands. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 36.36% since April 1, 2016 and is downtrending. It has underperformed by 37.58% the S&P500.

Analysts await Dimension Therapeutics Inc (NASDAQ:DMTX) to report earnings on December, 2. They expect $-0.50 EPS, up 81.68% or $2.23 from last year’s $-2.73 per share. After $-0.49 actual EPS reported by Dimension Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.04% negative EPS growth.

Dimension Therapeutics Inc (NASDAQ:DMTX) Ratings Coverage

Out of 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dimension Therapeutics has been the topic of 9 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The rating was initiated by Wells Fargo with “Outperform” on Friday, December 4. On Monday, November 16 the stock rating was initiated by Canaccord Genuity with “Buy”. The stock has “Buy” rating given by Citigroup on Monday, November 16. Goldman Sachs initiated Dimension Therapeutics Inc (NASDAQ:DMTX) on Friday, December 4 with “Buy” rating. The firm earned “Buy” rating on Thursday, February 18 by Cantor Fitzgerald. As per Friday, November 6, the company rating was initiated by Roth Capital. Goldman Sachs initiated Dimension Therapeutics Inc (NASDAQ:DMTX) rating on Monday, November 16. Goldman Sachs has “Buy” rating and $20 price target. Cantor Fitzgerald initiated Dimension Therapeutics Inc (NASDAQ:DMTX) rating on Friday, June 3. Cantor Fitzgerald has “Buy” rating and $32 price target.

According to Zacks Investment Research, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.”

More news for Dimension Therapeutics Inc (NASDAQ:DMTX) were recently published by:, which released: “In Latest Setback for Biotech IPOs, Dimension Therapeutics Shares Fall in Debut” on October 22, 2015.‘s article titled: “Dimension Therapeutics Inc.” and published on July 22, 2014 is yet another important article.

DMTX Company Profile

Dimension Therapeutics, Inc., incorporated on June 20, 2013, is a gene therapy company. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Firm has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV) vector delivery technology. The Firm uses mammalian cells in its manufacturing approach for its AAV product candidates. The Company’s AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment